Výsledky vyhledávání - "Johannes Nagelschmitz"

Akademický článek

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC

Autor: Eva M. Becker-Pelster, Michael G. Hahn, Martina Delbeck, Lisa Dietz, Jörg Hüser, Johannes Kopf, Thomas Kraemer, Tobias Marquardt, Thomas Mondritzki, Johannes Nagelschmitz, Sylvia M. Nikkho, Philippe V. Pires, Hanna Tinel, Gerrit Weimann, Frank Wunder, Peter Sandner, Joachim Schuhmacher, Johannes-Peter Stasch, Hubert K. F. Truebel

Publikováno v: Respiratory Research, Vol 23, Iss 1, Pp 1-15 (2022)

Abstract Background Oxidative stress associated with severe cardiopulmonary diseases leads to impairment in the nitric oxide/soluble guanylate cyclase signaling pathway, shifting native soluble guanylate cyclase toward heme-free apo-soluble guanylate

Externí odkaz: https://doaj.org/article/a7434a456b0646fda04bc3440b78080a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Results From Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3

Autor: Roland Heinig, Robert Fricke, Sebastian Wertz, Johannes Nagelschmitz, Stephanie Loewen

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics. 47:803-815

In vitro and in vivo studies were performed with the novel, selective, nonsteroidal mineralocorticoid receptor antagonist finerenone to assess the relevance of inhibitory effects on the transporters breast cancer resistance protein (BCRP), organic an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5866d7ef59f66b6e9832b3295802bd6c
https://doi.org/10.1007/s13318-022-00794-5

Zobrazit plný text záznamu

Results From Phase I Studies Investigating the Dose Linearity of Finerenone Tablets and the Influence of Food or pH-Modifying Comedications on its Pharmacokinetics in Healthy Male Volunteers

Autor: Roland Heinig, Johannes Nagelschmitz, Stephanie Loewen

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics. 47:549-559

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist that reduces the risk of adverse kidney and cardiovascular outcomes in patients with chronic kidney disease associated with type 2 diabetes mellitus. Clinical phase I studies with fin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d80bd91159fd0c185053ffb18a07bd40
https://doi.org/10.1007/s13318-022-00770-z

Zobrazit plný text záznamu

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease

Autor: E. C. Feleder, Jaime Altcheh, Johannes Nagelschmitz, Boris Weimann, G. A. Yerino, Facundo Garcia-Bournissen, Heino Stass

Publikováno v: Clinical Pharmacology in Drug Development
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Paediatrics Publications

Treatment of Chagas disease with nifurtimox requires age- and body weight-adjusted dosing, resulting in complex dosing instructions. Appropriate formulations are needed for precise and compliant dosing, especially in pediatric patients. We characteri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2153df56aac597d7a2e17ad7da0d4bdc
https://doi.org/10.1002/cpdd.871

Zobrazit plný text záznamu

Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial

Autor: Anne Kirsten, Frauke Pedersen, Tiemo-Joerg Bandel, Henrik Watz, Stephan Schwers, Klaus F. Rabe, Johannes Nagelschmitz, Dorina van der Mey

Publikováno v: Pulmonary Pharmacology & Therapeutics. 56:86-93

Background There are only limited treatment options for patients with non-cystic fibrosis bronchiectasis (non-CF BE). Human neutrophil elastase (HNE) is a mediator of tissue destruction in non-CF BE. BAY 85-8501, a selective and reversible HNE inhibi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f9bb132e7ddc591d00fb08fa970b115
https://doi.org/10.1016/j.pupt.2019.03.009

Zobrazit plný text záznamu

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment

Autor: Roland Heinig, Atef Halabi, Marc Lambelet, Johannes Nagelschmitz, Abir Alatrach

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics. 44:619-628

Finerenone (BAY 94-8862) is a selective, nonsteroidal mineralocorticoid receptor antagonist. The aim of this study was to assess the effect of mild or moderate hepatic impairment on the pharmacokinetics, safety and tolerability of finerenone. The stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a86ba5a18feb09e6fe8899fe9203918e
https://doi.org/10.1007/s13318-019-00547-x

Zobrazit plný text záznamu

Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications

Autor: Michaela Bairlein, Stephanie Loewen, Michael Gerisch, Roland Heinig, Johannes Nagelschmitz

Publikováno v: European journal of drug metabolism and pharmacokinetics. 45(4)

In vivo studies were performed with the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone to assess the relevance of inductive and/or inhibitory effects on cytochrome P450 (CYP) enzymes observed in vitro. CYP isoenzyme-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9e83a47b6bdfebc555a6823bde6afb
https://pubmed.ncbi.nlm.nih.gov/32125665

Zobrazit plný text záznamu

Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers

Autor: Knut Sommerer, Dominik Kappeler, Boris Weimann, Claudius Kietzig, Heino Stass, Johannes Nagelschmitz

Publikováno v: Journal of Aerosol Medicine and Pulmonary Drug Delivery. 30:53-63

Ciprofloxacin dry powder for inhalation (Ciprofloxacin DPI) is in development as long-term intermittent therapy to reduce the frequency of acute exacerbations in non-cystic fibrosis bronchiectasis (NCFB) patients with respiratory bacterial pathogens.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e60d5585280a8b872f9e1766227f06c
https://doi.org/10.1089/jamp.2015.1282

Zobrazit plný text záznamu

Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis

Autor: Knut Sommerer, Boris Weimann, Johannes Nagelschmitz, Dominik Kappeler, Heino Stass, Astrid Patzlaff

Publikováno v: Journal of aerosol medicine and pulmonary drug delivery. 32(3)

Background: As non-cystic fibrosis bronchiectasis (NCFB) progresses, patients suffer irreversible lung damage and deterioration in lung function. This study explored whether inhalational p...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edde76571fe936a9758a8cf7b918146e
https://pubmed.ncbi.nlm.nih.gov/30848695

Zobrazit plný text záznamu

Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study

Autor: Heino Stass, Heinz Delesen, Doris Staab, Johannes Nagelschmitz

Publikováno v: Journal of Aerosol Medicine and Pulmonary Drug Delivery. 28:106-115

Reliable, reproducible deposition to the lung is a major prerequisite for the clinical use of inhaled drugs. Ciprofloxacin dry powder for inhalation (ciprofloxacin DPI; Bayer HealthCare AG, Leverkusen, Germany) is an antibacterial therapy in developm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0734414bcbbbc3d1bedd3cd401e838e4
https://doi.org/10.1089/jamp.2013.1056

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání